November 6, 2012  6:00 – 8:30 p.m.
** PLEASE NOTE RESCHEDULED DATE **
PLEASE NOTE NEW START TIMES – PUBLIC SESSION STARTS AT 6:30 PM

1. Executive Session       6:00 - 6:30
   - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements
     (as provided by 33 VSA § 1998(f)(2))

2. Introductions and Approval of DUR Board Minutes   6:30 - 6:35
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates       6:35 - 6:45
   - Updates

4. Medical Director Update       6:45 - 6:50
   - Clinical Programs Update
   - Prescriber Comments

5. Follow-up Items from Previous Meetings       6:50 - 7:10
   - Atypical Antipsychotics – Pediatric Use
   - Antipsychotics in Children < 6 years old

6. RetroDUR/DUR 7:10 – 7:30
   - 90 Day Mandatory Fill Select Maintenance Medications
   - Suboxone®/Buprenorphine (also tablet market withdrawal)
   - Hepatitis C Protease Inhibitors

7. Clinical Update: Drug Reviews       7:30 – 7:45
   (Public comment prior to Board action)
   Full New Drug Reviews
   - Intermezzo® (zolpidem tartrate) Sublingual Tablet
   - Potiga® (ezogabine) Oral Tablet

8. Therapeutic Drug Classes – Periodic Review 7:45 – 8:00
   (Public comment prior to Board action)
   Class review documents available on DVHA web site 11/06/2012 @ 12 Noon
   - Inhaled Corticosteroid and Long-Acting β2-Agonist Combination Products
   - Platelet Inhibitors
   - Topical Androgens (testosterone)
9. New Managed Therapeutic Drug Classes 8:00 – 8:10
   (Public comment prior to Board action)
   - Miscellaneous: Makena® (also discussion of compounding pharmacies)

10. Review of Newly-Developed/Revised 8:10 – 8:20
    Clinical Coverage Criteria and/or Preferred Products
    (Public comment prior to Board action)
    - Incretin Mimetics
    - Short Acting β2-Agonist Inhalers
    - Statins

11. General Announcements 8:20 – 8:30
    Selected FDA Safety Alerts
    - Fungal Meningitis Outbreak Originating from Compounding Pharmacy
    - Pramipexole: Possible Risk of Heart Failure

12. Adjourn 8:30